<DOC>
	<DOCNO>NCT02546297</DOCNO>
	<brief_summary>The purpose study determine treatment effective safer patient COPD C group bronchiectasis.The research result help guide physician select appropriate individualize treatment hopefully provide evidence-based medicine proof revise guide .</brief_summary>
	<brief_title>Comparisons Inhaled LAMA ICS+LABA COPD With Bronchiectasis</brief_title>
	<detailed_description>The diagnosis treatment COPD bronchiectasis together seem complicated diagnosis treatment either condition alone . According GOLDï¼Œthere two treatment patient COPD group C : ICS combine LABA LAMA alone . However , yet demonstrate method effective patient COPD group C bronchiectasis . This study design prospective , randomize , case-control trial . Patients divide two group , one group inhale ICS LABA ( Symbicort ) , another group inhale LAMA ( Tiotropium Bromide ) .The course treatment 12 month . The treatment exchange 7th month . The investigator also assess relevant outcome , include quality life ( QOL ) score , pulmonary function test incidence adverse event .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Patients suitable inclusion study 18 year old diagnose COPD C group bronchiectasis . active tuberculosis severe respiratory disease ( Lung cancer , ARDS , pulmonary encephalopathy , respiratory failure ) uncontrollable diabetes hypersensitivity component ICS/LABA LAMA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>LAMA , ICS+LABA</keyword>
</DOC>